312 related articles for article (PubMed ID: 17000884)
1. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Deitcher SR; Kessler CM; Merli G; Rigas JR; Lyons RM; Fareed J;
Clin Appl Thromb Hemost; 2006 Oct; 12(4):389-96. PubMed ID: 17000884
[TBL] [Abstract][Full Text] [Related]
2. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
[TBL] [Abstract][Full Text] [Related]
3. Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
Hacobian M; Shetty R; Niles CM; Gerhard-Herman M; Vallurupalli N; Baroletti S; McKean SC; Sonis J; Parasuraman S; Kosowsky JM; Goldhaber SZ
Clin Appl Thromb Hemost; 2010 Feb; 16(1):21-5. PubMed ID: 19147527
[TBL] [Abstract][Full Text] [Related]
4. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
5. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
6. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
7. [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment].
Vorob'eva NM; Panchenko EP; Kirienko AI; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Andriiashkin VV; Leont'ev SG
Ter Arkh; 2009; 81(9):57-61. PubMed ID: 19827655
[TBL] [Abstract][Full Text] [Related]
8. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
9. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
Büller HR; Gallus AS; Pillion G; Prins MH; Raskob GE;
Lancet; 2012 Jan; 379(9811):123-9. PubMed ID: 22130488
[TBL] [Abstract][Full Text] [Related]
10. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
Castro DJ; Díaz G; Martí D; Escobar C; Ortega J; García-Rull S; Picher J; Sueiro A
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):173-7. PubMed ID: 17287635
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
[TBL] [Abstract][Full Text] [Related]
13. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
14. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
Poon IO; Lal L; Brown EN; Braun UK
J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
[TBL] [Abstract][Full Text] [Related]
15. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
Caine GJ; Lip GY
Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
[No Abstract] [Full Text] [Related]
16. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
Meyer G; Marjanovic Z; Valcke J; Lorcerie B; Gruel Y; Solal-Celigny P; Le Maignan C; Extra JM; Cottu P; Farge D
Arch Intern Med; 2002 Aug 12-26; 162(15):1729-35. PubMed ID: 12153376
[TBL] [Abstract][Full Text] [Related]
17. High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis.
Farahmand S; Saeedi M; Seyed Javadi HH; Khashayar P
Am J Emerg Med; 2011 Nov; 29(9):1222-6. PubMed ID: 21035980
[TBL] [Abstract][Full Text] [Related]
18. A practical approach for bridging anticoagulation after mechanical heart valve replacement.
Steger V; Bail DH; Graf D; Walker T; Rittig K; Ziemer G
J Heart Valve Dis; 2008 May; 17(3):335-42. PubMed ID: 18592932
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
20. Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Spinler SA; Friedman RJ
Ann Pharmacother; 2005 Nov; 39(11):1954-5; author reply 1955. PubMed ID: 16204385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
